The Anti-Leukemic Potential of Bee Venom

Preeti Solanki,1 Mohini Rana,1 Karnail Singh Choudhary,1 Vishal Ahuja,1 Vinay Kumar,2 Anuradha Tyagi3 1Department of Biotechnology-UCRD, Chandigarh University, Mohali, Punjab, 140413, India; 2College of Medicine, Pennsylvania State University Hershey Medical Center, Hershey, PA, 17033, USA; 3School of Medicine, University of Missouri, Columbia, MO, 65212, USACorrespondence: Anuradha Tyagi, Email [email protected] Preeti Solanki, Email [email protected]: Bee venom (BV) is a promising candidate against breast and lung, including leukemia. Leukemia is a malignancy related to blood cells that causes abnormal production of leukocytes (WBCs) from bone marrow (BM). Leukemia requires a multimodal treatment approach, including stem cell transplantation, immunotherapy, and chemotherapy. Due to several limitations of current therapies such as drug resistance, severe side effects, high costs, limited targeted treatment options, age-related restrictions, after treatment defects, and the genetic heterogeneity of leukemia, there is a need to explore alternatives such as BV, either as whole or its component(s), or its use in conjugation with other treatments. BV’s components such as melittin, found as 40– 60% of BV’s dry mass, exhibit anti-cancer activity such as pro-apoptotic, anti-proliferative, and cell membrane disruption. BV is a potent inducer of apoptosis, while inhibiting cell survival processes such as the Akt/ERK. BV can be considered as the potent anti-leukemia candidate. Various studies have demonstrated BVs effectiveness on leukemia cell lines such as HL-60, K562, Jurkat cell line, U937 cells, CCRF-CEM, K562, THP-1 cell lines, in a dose-time-cell line-dependent manner. This review aims to comprehend the current research assessing the effectiveness of apitherapy in leukemia through in vitro studies. The limitations of present studies and future possibilities exploring the synergistic effect of BV with the conventional treatments and targeted delivery of BV aimed at enhancing the effectiveness of treating leukemia are also highlighted. Keywords: bee venom, anti-cancer activity, melittin, apitherapy, dose-time-dependent response, anti-leukemia

Publication Details

Journal
Dove Medical Press (Taylor and Francis Group)
Published
2025-12-09
Primary Topic
Healthcare and Venom Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Anti-Leukemic Potential of Bee Venom

Dove Medical Press (Taylor and Francis Group)
Healthcare and Venom Research
article

The Anti-Leukemic Potential of Bee Venom

article en

Abstract

Preeti Solanki,1 Mohini Rana,1 Karnail Singh Choudhary,1 Vishal Ahuja,1 Vinay Kumar,2 Anuradha Tyagi3 1Department of Biotechnology-UCRD, Chandigarh University, Mohali, Punjab, 140413, India; 2College of Medicine, Pennsylvania State University Hershey Medical Center, Hershey, PA, 17033, USA; 3School of Medicine, University of Missouri, Columbia, MO, 65212, USACorrespondence: Anuradha Tyagi, Email [email protected] Preeti Solanki, Email [email protected]: Bee venom (BV) is a promising candidate against breast and lung, including leukemia. Leukemia is a malignancy related to blood cells that causes abnormal production of leukocytes (WBCs) from bone marrow (BM). Leukemia requires a multimodal treatment approach, including stem cell transplantation, immunotherapy, and chemotherapy. Due to several limitations of current therapies such as drug resistance, severe side effects, high costs, limited targeted treatment options, age-related restrictions, after treatment defects, and the genetic heterogeneity of leukemia, there is a need to explore alternatives such as BV, either as whole or its component(s), or its use in conjugation with other treatments. BV’s components such as melittin, found as 40– 60% of BV’s dry mass, exhibit anti-cancer activity such as pro-apoptotic, anti-proliferative, and cell membrane disruption. BV is a potent inducer of apoptosis, while inhibiting cell survival processes such as the Akt/ERK. BV can be considered as the potent anti-leukemia candidate. Various studies have demonstrated BVs effectiveness on leukemia cell lines such as HL-60, K562, Jurkat cell line, U937 cells, CCRF-CEM, K562, THP-1 cell lines, in a dose-time-cell line-dependent manner. This review aims to comprehend the current research assessing the effectiveness of apitherapy in leukemia through in vitro studies. The limitations of present studies and future possibilities exploring the synergistic effect of BV with the conventional treatments and targeted delivery of BV aimed at enhancing the effectiveness of treating leukemia are also highlighted. Keywords: bee venom, anti-cancer activity, melittin, apitherapy, dose-time-dependent response, anti-leukemia

Dove Medical Press (Taylor and Francis Group)
Good health and well-being
Openalex Percentile: Top 33%
Healthcare and Venom Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.